April 28, 2016
Nanoscale magnets offer a new way to find faint, early traces of cancer in patients, according to Rice University students working on a method to capitalize on the magnets’ properties.
September 02, 2015
Marvin Maslow may not be as well-known as investors George Soros, Michael Milken or David Bonderman. But one thing he has in common with those marquee names is his goal of bringing experimental cancer-fighting technology to market.
July 20, 2015
Pursuing his new and very personal interest in the latest cancer treatments and technologies, Texas blogger and book author Al Petter recently wrote about his opportunity to get a behind-the-scenes look at what is happening at MD Anderson in advanced cancer research.
June 26, 2015
In a newly released publication, Magnetic Relaxometry has been demonstrated to be more than 100 times more sensitive than previously reported. The optimized method can detect, localize, and quantify cancer cells with sensitivity and precision greatly exceeding alternative methods such as mammography and ultrasound imaging, making it an ideal platform for the in vivo detection of solid tumors.
Download the publication here.
June 25, 2015
The New Nano Particle Lab at our Albuquerque facility is almost complete. Read more to see a few photos of the lab.
May 11, 2015
Cancer continues to be one of the leading causes of mortality globally. Despite technical advances in science and medicine made in the last 150 years we still lack effective forms of therapy for many types of cancer, and the general consensus within the medical community is that more lives could be saved if cancer could be detected earlier.
March 27, 2015
In the report they highlight the CINT/Senior Scientific collaboration efforts.
February 24, 2015
MD Anderson has created and published a link to its Magnetic Relaxometry Research Laboratory featuring our MRX II instrument and technology. The principal investigator is Dr. John D. Hazle, PhD, Professor & Chairman of the Imaging Physics Department at MD Anderson Cancer Center
February 02, 2015
Kayla Minser, M.S.,has joined our team as Biomedical Research Associate. Ms. Minser holds an M.S. in Biological Sciences from Purdue University, where she studied the mechanisms of breast cancer metastasis and methods by which to inhibit metastatic spread in vitro and in vivo. She will be supporting ongoing biological studies using functionalized nanoparticles in cell and animal models.
Andrew Gomez, M.S. has joined our team as a Process Development Engineer and lab manager. Mr. Gomez will soon receive his M.S. in Biomedical Engineering from the University of New Mexico, where he has been studying biologically inspired nanomaterials for drug delivery and monitoring in vivo. He will support nanoparticle production efforts for both commercial and internal R&D use.
November 04, 2014
We are happy to report that Dr. Flynn is quoted in the article, "Take a Nano Pill and Call Google in the Morning?" published by TechNewsWorld. The article includes quotes from many prestigious researchers such as those at Quinnipiac University, Baruch College and the American Institute for Behavioral Research and Technology, so Dr. Flynn is positioned as an industry thought leader among stellar company!
September 29, 2014
Chief Nanoparticle Chemist at Senior Scientific Dr. Erika Vreeland, presented our nanoparticle work at the National Lab Day in Washington: “How the National Labs Keep Moving America Forward”. She met and spoke with United States Secretary of Energy, Dr. Ernest Moniz.
June 12, 2014
This film was created by a film crew from the Los Alamos Laboratory to be part of the ongoing exhibit on nanotechnology at the Bradbury museum in Los Alamos for the Center for Integrative Nanotechnologies (CINT). It consists of interviews with Dr. Dale Huber and Edward R. Flynn which are partially overlaid visually by ongoing experiments and experimental results.
The beginning of the film consists of the early history of Dr. Flynn’s experience in biomagnetism which began the 90’s. Also shown is a large SQUID sensor for measuring magnetic fields from the brain using 155 SQUID sensors, along with some measurements of fields from the brain.
The historical content is followed by showing our own Leyma DeHaro recording data that is being taken on cancer cells using the magnetic relaxometry instrument and this is followed by the showing of confocal images of cancer cells.
The film also includes the analysis procedure for these cancer cells, showing the extraction of magnetic field contour lines from the data and the method the analysis code uses for multiple magnetic sources.
In addition, Senior Scientific’s Erika Vreeland is shown with the apparatus for making the magnetic nanoparticles at CINT and some of the results characterizing these nanoparticles including TEM images and size analysis.
June 11, 2014
The MRX II is up and running at MD Anderson! At the heart of the instrument are the multiple SQUID detectors working together to detect a signal from the bound nanoparticles in a sample. Based on the first generation system created by Ed Flynn himslef, the MRX II instrument includes new hardware and electronics to provide even better performance and seviceability in the field.
April 14, 2014
Building upon local relationships, Senior Scientific is stepping into the commercial space with first product introductions through Azano Biotech. Azano currently supplies research reagents to the same cancer researchers who will eventually be customers for the MRX II instrument.
March 19, 2014
The overarching mission for February has been to get the 9 Channel System up and running. We are delighted to be delivering this extraordinary device to our collaborators at MD Anderson.
December 11, 2013
Leyma De Haro, Ph.D., has joined Senior Scientific LLC as our Biomedical Applications Scientist. Ms. De Haro has a PhD in Biomedical Sciences from the University of New Mexico, and was most recently a Postdoctoral Research Scientist in the Bioscience Division of Los Alamos National Laboratories
October 01, 2013
Manhattan Scientifics, Inc. closed the second tranche of financing in the amount of $500,000 under the financing agreement entered with Raymond A. Mason, William B. Jones and the Ferdinand J. Crovato Trust
August 05, 2013
To promote the company's first NanoMRX commercial instrument and to initiate the “instrument production on demand” and “fee for service” programs.
August 01, 2013
Magnetic relaxometry methods have been shown to be very sensitive in detecting cancer cells and other targeted diseases. Superconducting Quantum Interference Device (SQUID) sensors are one of the primary sensor systems used in this methodology because of their high sensitivity with demonstrated capabilities of detecting fewer than 100,000 magnetically-labeled cancer cells.